AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02971306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical therapy
Description: Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
Study NCT00422487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-2044
Description: MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
Study NCT02971306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
Study NCT00422487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MBX-2044
Description: Placebo Intervention
Study NCT01668823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV
Study NCT01668823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo photodynamic therapy with HPPH
Study NCT01668823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic bronchoscopy
Description: Undergo therapeutic bronchoscopy for endoscopic debridement
Study NCT02390310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shang Ring
Description: Comparison of healing times at 7 day and more than 7 days after circumcision.
Study NCT02390310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injectable anesthesia (lidocaine 1%)
Description: Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
Study NCT02390310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)
Description: Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
Study NCT03983798 — intervention group
Intervention type: OTHER
Intervention: Simulation training in psychiatry
Description: Each participant will complete 6 hours of psychiatric simulation training, dealing with mood disorders, anxious disorders, eating disorders, borderline disorders, substance abuse and schizophrenia. Simulation training will be supplemented by brief lecture on concept map and portfolio at the beginning of the first hour.~Curriculum integration of simulation training in psychiatric course assure that each pathology studied is supplemented by a one-hour lecture and 1 to 3 hours clinical cases and MCQ training. A part of the medical students are supplemented by clinical practice ; whereas the other won't benefit from clinical practice.
Study NCT02510950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccine
Study NCT02510950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Study NCT02510950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT02665377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANP
Study NCT02665377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02971306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-Acetylcysteine
Description: n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
Study NCT02191852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seresis®
Study NCT06678776 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: Explore the relationship between breast fascia development and surgical processes by repeatedly observing surgical videos of endoscopic mastectomy and reduction mammaplasty.
Study NCT02334332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02942095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase
Study NCT02574338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley's Catheter
Description: intracervical extraamniotic Foley's catheter
Study NCT02942095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.
Study NCT02432001 — intervention group
Intervention type: PROCEDURE
Intervention: Image-Guided Biopsies
Study NCT01576016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accent MRI system (lead safety)
Description: Patients implanted with an Accent MRI system
Study NCT01576016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accent MRI system (with MRI scan)
Description: Patients implanted with an Accent MRI system will receive an MRI scan
Study NCT02280967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education about HPV by school nurse
Description: Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
Study NCT02574338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prostaglandin E1 analogue
Description: intravaginal misoprostol
Study NCT01446224 — intervention group
Intervention type: DRUG
Intervention: Pazopanib
Description: Patients treated with pazopanib
Study NCT00243334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integration of advanced clinical decision support with ambulatory computerized physician order entry
Description: Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
Study NCT00540813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug eluting balloon
Description: drug eluting balloon bifurcated coronary lesions single arm study
Study NCT03978533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Support Group
Description: Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
Study NCT03354169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Condition
Description: Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
Study NCT04392349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Haag-Streit EYESTAR 900
Description: The EYESTAR 900 is a new device developed by HAAG-STREIT AG which utilises Optical Coherence Tomography (OCT) for quantitative measurements of the geometry of the eye. As a successor to the LENSTAR 900, it represents the most recent in a series of successful biometry devices.
Study NCT04392349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tomey CASIA 2
Description: The CASIA2 is a testing application for Cataract / Glaucoma / Cornea Surgery already established on the market. It is a representative device for measurement of anterior and posterior corneal curvature (anterior and posterior corneal topography) by optical coherence tomography, and for measurement of crystalline lens tilt by optical coherence tomography.
Study NCT04392349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Oculus PENTACAM HR
Description: The Pentacam HR is a high-resolution rotating Scheimpflug camera system for anterior segment analysis already established on the market. It is used as representative device for advanced anterior segment analysis such as anterior and posterior corneal topography and corneal pachymetry.
Study NCT04392349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zeiss ATLAS 9000
Description: ATLAS is a corneal topography system used as representative device for measurement of anterior corneal curvature (anterior corneal topography).
Study NCT03227549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Superior Approach
Description: Total hip arthroplasty using direct superior approach
Study NCT03227549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty using direct superior or posterior approach
Study NCT02145156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored educational materials
Description: The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
Study NCT03227549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty using direct superior or posterior approach
Study NCT03227549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Approach
Description: Total Hip Arthroplasty using posterior approach
Study NCT02396992 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Minimal-Massive Intervention
Description: The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
Study NCT03875248 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Blood pressure measurement
Description: Measure optically the blood pressure through the use of a smartphone
Study NCT03264248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Scale
Description: Daily bodyweight system used under legs of bed
Study NCT02939495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine/Sildenafil 30/50 mg film coated tablet
Description: 1 tablet before sexual intercourse
Study NCT00513734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel dressing
Description: 3x3cm hydrogel dressing over closed eye
Study NCT00513734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lacrilube ointment
Description: lubricant put into eye (inferior formix)
Study NCT04081506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized perfusion targets
Description: Targeting +/-5mmHg of the optimal mean arterial pressure
Study NCT02488174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROOFcheck
Study NCT02488174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study NCT00280488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview
Description: Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
Study NCT04026191 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OrthoVisc®-T (OVT)
Description: Sodium hyaluronate supplied as a 2 mL (15mg/mL) unit dose in a 3 mL glass syringe.
Study NCT02973243 — intervention group
Intervention type: DEVICE
Intervention: Automatic RR Measurement
Description: Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
Study NCT03237936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg/mL ciclosporin
Description: IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
Study NCT00280488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment
Description: In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
Study NCT03651531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.
Study NCT03651531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
Study NCT04914936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.
Study NCT04914936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Participants will receive a single oral dose of calcium carbonate 1 g tablet on Day 1 of Period 2 in Part 1.
Study NCT04914936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants will receive multiple oral doses of omeprazole 40 mg capsules QD for 5 consecutive days in Period 2 of Part 2.
Study NCT04914936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Participants will receive multiple oral doses of rifampin 600 mg capsule QD for 9 consecutive days in Period 2 of Part 3.
Study NCT02848027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regenexx SD® procedure
Description: Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
Study NCT02145156 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Untailored educational materials
Description: The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention.
Study NCT02145156 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey-only
Description: Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
Study NCT01631279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR610
Description: Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
Study NCT02512003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fantom Scaffold
Study NCT01889446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium propionate
Study NCT01955863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient discharge on postoperative day 2
Description: The patient was discharge on postoperative day 2 (as was done routinely)
Study NCT01955863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient discharge on postoperative day 1
Description: The patient was discharge on postoperative day 1
Study NCT01955863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient discharge in the day of surgery
Description: The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
Study NCT02268656 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: propofol concentration
Description: First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
Study NCT03376282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperbaric Oxygen oxygen therapy (HBOT)
Description: 60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
Study NCT01756742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy
Description: The respiratory physiotherapy intervention included:~* Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~* Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry.
Study NCT01756742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conservative treatment
Description: Conservative medical treatment intervention for pleural effusion.
Study NCT06537687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A standardized handout on HPV and vaccine education will be given
Study NCT03099824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-101
Description: 82 mg (1 capsule)
Study NCT06537687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A video about HPV and vaccines on a tablet provided by a research assistant
Study NCT03361631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow derived Mesenchymal Stem Cells
Description: Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination \& Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores \& Pharmaco-Doppler
Study NCT01442610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Rasagiline tablets 1mg once daily for 8 weeks
Study NCT01442610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1tablet once daily for 8 weeks
Study NCT02343185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy with diaphragmatic treatment
Description: Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
Study NCT02343185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
Study NCT00330733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate
Description: Participants were randomized to 12-week treatment with up to 4 g/day.
Study NCT00330733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomized to 12-week treatment matching the active salsalate arm.
Study NCT02382146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone ondansetron
Description: dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
Study NCT02382146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone dimenhidrinate
Description: dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
Study NCT03246880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin 0.2mg
Description: per oral for 12weeks after 2\~4weeks run-in period
Study NCT03246880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2mg
Description: per oral for 12weeks after 2\~4weeks run-in period
Study NCT01446224 — intervention group
Intervention type: DRUG
Intervention: Other anti-VEGFs
Description: Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
Study NCT03099824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV GC4419
Description: GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
Study NCT02838940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples.
Description: At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation.
Study NCT02838940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.